Nov 14 (Reuters) – Novo Nordisk A/S: * NOVO NORDISK: CAGRISEMA 1.7 MG/1.7 MG ACHIEVED 20.7%, 1.0 MG/1.0 MG ACHIEVED 21.0% AVERAGE WEIGHT LOSS AT 68 WEEKS VERSUS 2.0% WITH PLACEBO IN REDEFINE 9 TRIAL *
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)